Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

A drug for a rare obesity condition keeps working — and working. Two-year data from the TRANSCEND trial extension show setmelanotide (Imcivree) sustained significant BMI reductions in both adults and children with acquired hypothalamic obesity. Even patients who started on placebo and switched to the drug in year two saw robust BMI declines, reinforcing the treatment's durability for a condition with very few options.
Two-year data confirm setmelanotide's staying power in hypothalamic obesity
Patients with acquired hypothalamic obesity — a condition marked by relentless, progressive weight gain — now have stronger evidence supporting long-term treatment with setmelanotide (Imcivree). Results from the open-label extension of the TRANSCEND trial, presented at ObesityWeek, show that BMI reductions achieved in year one were not only maintained but slightly improved at the two-year mark.
Crucially, patients who had been on placebo during the first year and crossed over to setmelanotide in year two experienced dramatic BMI drops, mirroring the results of those who had been on the drug all along. Lead presenter Dr. Susan A. Phillips described the crossover effect as "black and white," underscoring how directly the drug drives weight reduction in this population.
By the Numbers:
Why it matters: Acquired hypothalamic obesity is a rare but serious condition, often affecting children as young as 4. With setmelanotide already approved for this age group, these two-year results give clinicians — especially pediatric endocrinologists — compelling evidence to consider this therapy for eligible patients who previously had very limited treatment options.